UNITED NATIONS OFFICE FOR PROJECT SERVICES (UNOPS)

FINANCIAL AUDIT REPORT

21 December 2021

PROJECT NAME: FIRST LINE ANTI-TB DRUGS PROCUREMENT 2019
PROJECT NUMBER: 21262-003
COUNTRY: MYANMAR
AUDITOR: BDO LLP
PERIOD SUBJECT TO AUDIT: 1 JANUARY 2019 TO 30 SEPTEMBER 2021
Contents

Acronyms and abbreviations ................................................................. 3

Financial audit report .......................................................................... 4
  Audit opinion on the project financial statement .................................. 4

Annex I – Project financial statement
Annex II – Responsibility statement by management
Acronyms and abbreviations

ARV  Anti-retroviral
FLD  First line drugs
HIV  Human Immunodeficiency Virus
IAIG  Internal Audit and Investigations Group
IESBA  International Ethics Standards Board for Accountants
ISA  International Standards on Auditing
UNOPS  United Nations Office for Project Services
US$  United States Dollars
Financial audit report

Audit opinion on the project financial statement

Unmodified opinion

We have audited the accompanying project financial statement for the project ‘First Line Anti-TB Drugs Procurement 2019’ ("the project") (oneUNOPS project ID 21262-003), which is implemented and managed by the UNOPS Office in Myanmar, for the period from 1 January 2019 to 30 September 2021.

In our opinion, the financial statement gives a true and fair view of, in all material respects, the income and expenditure of the project, for the period from 1 January 2019 to 30 September 2021 in conformity with the terms of the agreements and in accordance with International Public Sector Accounting Standards.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those provisions and standards are further described in the ‘Auditor’s responsibility for the audit of the project financial statement’ section of this report.

We are independent of UNOPS in accordance with the IESBA Code of Ethics for Professional Accountants. We have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management responsibility for the financial statement

Management is responsible for the preparation and fair presentation of the financial statement in accordance with International Public Sector Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of a financial statement that is free from material misstatement, whether due to fraud or error.

Auditor’s responsibility for the audit of the project financial statement

The objectives of our audit are set out in the terms of reference for the audits of UNOPS projects, as issued by the Internal Audit and Investigations Group (IAIG) of UNOPS and include obtaining reasonable assurance about whether the project financial statement is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the decisions of users taken on the basis of the project financial statement.
As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also identify and assess the risks of material misstatement of the project financial statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Project financial statement**

This is attached as Annex I to this report.

Robert Waters
Partner

BDO LLP
55 Baker Street
London W1U 7EU

XX December 2021
Responsibility statement by management

This is attached as Annex II to this report.
Annex I – Project financial statement
Dear Sir/Madam,

Subject: **Interim Financial Statement**

We enclose the Interim Financial Statement for **project 21262-003** - First line Anti-TB Drugs Procurement 2019, which commenced in year 2019 and indicates the incurred expenditure as at 30/09/2021.

We draw your attention to the following:

a. Incurred expenditure and management fee: US$ **2,844,502**

b. Project advances: US$ **0** and commitments: US$ **9,950**

c. Total funds received: US$ **2,866,660** which includes interest earned: US$ **0**

d. Project Capitalised Asset: US$ **0**

e. Fund Surplus: US$ **12,208**

If you have any question, please do not hesitate to contact UNOPS.

Yours sincerely,

Meron MEKURIW, Finance Specialist, SSC IPAS
## INTERIM FINANCIAL STATEMENT

**Project:** 21262-003 - First line Anti-TB Drugs Procurement 2019  
**Partner(s):** 1382 - Myanmar  
**As on:** 30-Sep-2021

### Income:
<table>
<thead>
<tr>
<th>Contributions</th>
<th>2019</th>
<th>2,866,660</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td>A</td>
<td>2,866,660</td>
</tr>
</tbody>
</table>

### Less: Project Expenses

<table>
<thead>
<tr>
<th>Period-Years</th>
<th>Project(s) Expense</th>
<th>Management Fees</th>
<th>Net Exchange Gain/Loss</th>
<th>Total Expenditure</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>1,462,334</td>
<td>43,724</td>
<td></td>
<td>1,506,058</td>
</tr>
<tr>
<td>2020</td>
<td>1,299,366</td>
<td>38,851</td>
<td></td>
<td>1,338,217</td>
</tr>
<tr>
<td>2021</td>
<td>220</td>
<td>7</td>
<td></td>
<td>227</td>
</tr>
</tbody>
</table>

### Total Expenditure  
| B            | 2,844,502 |

### Less: Project Advances  
| C            | 0         |

### Less: Project Capitalised Assets  
| D            | 0         |

### Project Cash Balance  
| A-B-C-D      | 22,158    |

### Less: Actual Commitments  
| Commitments | E         | 9,950     |

### A-B-C-D-E  
| 12,208       |

**Notes:**  
* All amounts are in USD. Transactions in non-USD have been converted to USD at the UN operational rate of exchange as on the date of the transaction.  
* This is an interim statement provided for information purposes only. Figures are not final.  
* The report includes fee projections for open period(s).
Date: 02 Dec 2021

Report run on: 01 Oct 2021
Annex II – Responsibility Statement by Management
UNITED NATIONS OFFICE FOR PROJECT SERVICES

Project ID: 21262-003

First line Anti-TB Drugs Procurement 2019

RESPONSIBILITY STATEMENT by MANAGEMENT

The United Nations Office for Project Services (UNOPS) management is responsible for the preparation, integrity and fair presentation of the Financial Statements of the Project ID 21262-003, Project name: First line Anti-TB Drugs Procurement 2019.

The Statement, presented in Annex I, has been prepared in accordance with the applicable UNOPS regulations and rules.

We do hereby state that, in our opinion:

Interim Financial Statement

The Interim Financial Statement as reported, as set out in Annex I, presents fairly in all material respects, the expenditure of US$2,844,502 (In words: United States Dollar Two Million Eight Hundred Forty Four Thousand Five Hundred and Two only) incurred by the UNOPS office for the period 1 January 2019 to 30 September 2021 in accordance with the accounting policies set out in the Notes to the Statement and in conformity with approved activities and budgets for Project ID 21262-003, Project name: First line Anti-TB Drugs Procurement 2019.

ACCEPTED AND CERTIFIED:

Dr. Attila Molnar  Meron Mekuriaw  Sanjay Mathur

Name: Dr. Attila Molnar  Name: Meron Mekuriaw  Name: Sanjay Mathur
Programme Director  Finance Specialist  Regional Director
Project: PR-GFATM, UNOPS Asia Region SSC, IPAS Finance  UNOPS Asia Region
Region: AR  Region: UNOPS – HQ  Region: AR
Place: Yangon, Myanmar  Place: Copenhagen, Denmark  Place: Bangkok, Thailand
Date: 8 December 2021  Date: 9 December 2021  Date: 12 December 2021